We describe two patients with metastatic prostate cancer who developed rapid clinical progression accompanied by disproportionately low prostate-specific antigen (PSA) levels, ultimately revealing transformation to neuroendocrine carcinoma. The gene discussed is KLK3; the disease is neuroendocrine carcinoma.